在乳腺癌治疗期间，大约一半的患者会服用精神药物，例如选择性血清素再摄取抑制剂（SSRI）。草酸艾司西酞普兰是一种用作抗抑郁药的SSRI。本研究通过与THP-1、MCF-7和MDA-MB-231创建乳腺癌微环境，创建了乳腺癌共培养模型。MCF-7、MDA-MB -231和THP-1细胞系确定草酸艾司西酞普兰细胞毒作用的浓度范围采用MTS和MTT试验。 IC50 值由 xCELLigence 实时细胞分析 (RTCA) 系统测定。通过流式细胞术测定细胞凋亡活性和细胞因子水平。根据结果进行xCELLigence实时分析，测得草酸艾司西酞普兰的IC50值对于MCF-7为13.7μM，对于MDA-MB-231为10.9μM。在使用他莫昔芬的 xCELLigence 分析中，MCF-7 的 IC50 值为 54.6 μM，MDA-MB-231 的 IC50 值为 58.4 μM。根据MTS测试结果，他莫昔芬对THP-1的IC50值为92.03μM，对草酸艾司西酞普兰的IC50值为95.32μM。在共培养模型中，草酸艾司西酞普兰对MCF-7细胞的免疫学影响对于白细胞介素（IL）-1β、IL-6、IL-8、 IL-10和TNF-α分别对MB-231细胞的作用分别为2.1%、15.9%、16.2%、8.8%和11.8%。根据所得结果得出结论：草酸艾司西酞普兰的免疫学作用比他莫昔芬更有效，可用作乳腺癌治疗的辅助药物。© 2024 Nalan Biriz 等人，由 Sciendo 出版。

During breast cancer treatment, approximately half of the patients are prescribed psychotropic medication, such as selective serotonin reuptake inhibitors (SSRIs). Escitalopram oxalate is an SSRI used as an antidepressant.In this study, by creating a breast cancer microenvironment with THP-1, MCF-7 and MDA-MB-231 breast cancer co-culture models were created.MCF-7, MDA-MB-231, and THP-1 cell lines to determine the concentration range of the cytotoxic effect of escitalopram oxalate MTS and MTT test were used. IC50 values were determined by the xCELLigence real-time cell analysis (RTCA) system. Apoptotic activities and cytokine levels were determined by flow cytometry.In the xCELLigence real-time analysis made according to the results, the IC50 value of escitalopram oxalate was measured as 13.7 μM for MCF-7 and 10.9 μM for MDA-MB-231. The IC50 value was measured as 54.6 μM for MCF-7 and 58.4 μM for MDA-MB-231 in xCELLigence analysis with tamoxifen. According to the MTS test results, the IC50 value of tamoxifen for THP-1 was 92.03 μM and the IC50 value for escitalopram oxalate was 95.32 μM. In the co-culture model, the immunological effects of escitalopram oxalate on MCF-7 cells were 2.8%, 11.1%, 15.6%, 10.6%, and 12.1% for interleukin (IL)-1β, IL-6, IL-8, IL-10, and TNF-α, respectively, while MDA effects on MB-231 cells, respectively, were 2.1%, 15.9%, 16.2%, 8.8%, and 11.8%.According to the results obtained, it was concluded that the immunological effects of escitalopram oxalate are more effective than tamoxifen and that it can be used as an adjunctive agent in breast cancer treatment.© 2024 Nalan Biriz et al., published by Sciendo.